Literature DB >> 21632230

HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody.

Kiminobu Tanizawa1, Tomohiro Handa, Ran Nakashima, Takeshi Kubo, Yuji Hosono, Kizuku Watanabe, Kensaku Aihara, Toru Oga, Kazuo Chin, Sonoko Nagai, Tsuneyo Mimori, Michiaki Mishima.   

Abstract

BACKGROUND: Anti-CADM-140 antibody (anti-CADM-140), also referred to as anti-melanoma differentiation-associated gene 5 (MDA5) antibody, is a myositis-specific antibody identified in the sera of patients with clinically amyopathic dermatomyositis (C-ADM) and is associated with a worse prognosis in dermatomyositis-associated interstitial lung disease (DM-ILD). We sought to determine high-resolution computed tomography (HRCT) features of DM-ILD with anti-CADM-140.
METHODS: Twenty-five patients newly diagnosed with DM-ILD at Kyoto University Hospital between 2005 and 2009 were retrospectively reviewed. Serum anti-CADM-140 was measured in all patients at their first visit. Chest HRCT images taken prior to treatment were classified based on the dominant findings and their distribution, and compared between patients with and without the antibody.
RESULTS: Of 25 DM-ILD patients, 12 were positive and 13 were negative for anti-CADM-140. HRCT patterns differed significantly between anti-CADM-140-positive and negative patients (P = 0.002). Lower consolidation or ground-glass attenuation (GGA) pattern (50.0%) and random GGA pattern (33.3%) were the predominant patterns in anti-CADM-140-positive cases, while lower reticulation pattern (69.2%) was frequently seen in anti-CADM-140-negative cases. Anti-CADM-140-positive cases were also significantly characterized by the absence of intralobular reticular opacities (0% in anti-CADM-140 (+) vs. 84.6% in anti-CADM-140 (-), P < 0.0001).
CONCLUSIONS: Anti-CADM-140-positive DM-ILD was characterized by lower consolidation or GGA pattern, random GGA pattern, and the absence of intralobular reticular opacities.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632230     DOI: 10.1016/j.rmed.2011.05.006

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  35 in total

1.  Anti-MDA5-Positive Dermatomyositis Presenting as Fever of Unknown Origin.

Authors:  Lori W Lee; Neera S Narang; Anna Postolova; Nicole Seminara; Molly A Kantor
Journal:  J Gen Intern Med       Date:  2016-12       Impact factor: 5.128

Review 2.  Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.

Authors:  Wanlong Wu; Li Guo; Yakai Fu; Kaiwen Wang; Danting Zhang; Wenwen Xu; Zhiwei Chen; Shuang Ye
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-06       Impact factor: 8.667

Review 3.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

4.  Utility of Coagulation Markers for the Prediction of Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis.

Authors:  Tomoya Sagawa; Takashi Kida; Tohru Inaba; Isao Yokota; Risa Sagawa; Akiko Kasahara; Shunya Kaneshita; Takuya Inoue; Hidetake Nagahara; Kazuki Fujioka; Makoto Wada; Masataka Kohno; Yutaka Kawahito
Journal:  Lung       Date:  2019-06-25       Impact factor: 2.584

5.  Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies.

Authors:  Amandine Laporte; Kubéraka Mariampillai; Yves Allenbach; Nicoletta Pasi; Victoria Donciu; Dan Toledano; Benjamin Granger; Olivier Benveniste; Philippe A Grenier; Samia Boussouar
Journal:  Eur Radiol       Date:  2022-01-13       Impact factor: 5.315

6.  18F-FDG PET/CT and HRCT: a combined tool for risk stratification in idiopathic inflammatory myopathy-associated interstitial lung disease.

Authors:  Yuying Zhang; Zhifeng Chen; Yali Long; Bing Zhang; Qiao He; Kejing Tang; Xiangsong Zhang
Journal:  Clin Rheumatol       Date:  2022-06-27       Impact factor: 3.650

Review 7.  [Dermatomyositis-update].

Authors:  B Volc-Platzer
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

Review 8.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

Review 9.  The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum.

Authors:  Elizabeth Ghazi; Richard D Sontheimer; Victoria P Werth
Journal:  Clin Exp Rheumatol       Date:  2012-11-22       Impact factor: 4.473

Review 10.  Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?

Authors:  Sarah L Tansley; Neil J McHugh; Lucy R Wedderburn
Journal:  Arthritis Res Ther       Date:  2013-04-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.